Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at Stifel Following 4Q
March 1, 2017 9:00 AM ESTStifel lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $200.00) while maintaining a Buy rating.
Analyst Annabel Samimy commented, "JAZZ reported 4Q16 revenue of $396.6mn (Cons. $398.3mn), representing +16.4% y/y. Top-line was driven by Xyrem with sales of $291.2mn (Cons.... More
